CU23403A1 - Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores - Google Patents
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumoresInfo
- Publication number
- CU23403A1 CU23403A1 CU20030092A CU20030092A CU23403A1 CU 23403 A1 CU23403 A1 CU 23403A1 CU 20030092 A CU20030092 A CU 20030092A CU 20030092 A CU20030092 A CU 20030092A CU 23403 A1 CU23403 A1 CU 23403A1
- Authority
- CU
- Cuba
- Prior art keywords
- ganglioside
- glicolil
- diagnosis
- recombinant antibodies
- tumor treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se relaciona fundamentalmente con la producción de inmunoglobulinas menos inmunogénicas por la vía de la ingeniería genética, y más específicamente con un anticuerpo monoclonal que reconoce antígenos que contienen el gangliósido N-glicolil o N-acetil, ni a los glicolípidos sulfatados. Mas específicamente la presente invención se relaciona con las secuencias peptídicas que codifican un anticuerpo monoclonal recombinante contra el gangliósido n-glicolil GM3, o fragmentos derivados del mismo y composiciones farmacéuticas conteniendo dicho anticuerpo o sus fragmentos y su uso tanto diagnóstico o terapéutico en cáncer de mama y melanoma.
Priority Applications (34)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
CL200400843A CL2004000843A1 (es) | 2003-04-23 | 2004-04-21 | ANTICUERPO MONOCLONAL RECOMBINANATE Y FRAGMENTO Fv DERIVADO DEL ATICUERPO MONOCLONAL MURINO 14F7 PRODUCIDO POR EL HIBRIDOMA CON NUMERO DE DEPOSITO ECACC 98101901 QUE RECONOCE EL GANGLIOSIDO N-GLICOLIL GM3; COMPOSICION FARMACEUTICA QUE LO CONTIENE; Y |
PE2004000397A PE20050422A1 (es) | 2003-04-23 | 2004-04-21 | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 |
CA2523449A CA2523449C (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumours |
CNA2004800174578A CN1809592A (zh) | 2003-04-23 | 2004-04-22 | 识别n-乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用 |
NZ543345A NZ543345A (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments recognizing ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumors |
AU2004232391A AU2004232391B2 (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments recognising ganglioside N-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours |
SI200432242T SI1623997T1 (sl) | 2003-04-23 | 2004-04-22 | Rekombinantno protitelo in fragmenti prepoznajoč gangliozid n-glikolil-gm3 in njih uporaba za diagnozo in zdravljenje tumorjev |
PCT/CU2004/000006 WO2004094477A1 (es) | 2003-04-23 | 2004-04-22 | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores. |
BRPI0409664-9A BRPI0409664A (pt) | 2003-04-23 | 2004-04-22 | anticorpo recombinante, fragmento fv de cadeia simples derivado do anticorpo monoclonal murino 14f7, linhagem celular, composição farmacêutica e reativo para a localização e identificação "in vivo" de tumores malignos |
PL04728755T PL1623997T3 (pl) | 2003-04-23 | 2004-04-22 | Rekombinowane przeciwciała i fragmenty rozpoznające gangliozyd n-glikolilo-gm3 i ich zastosowanie w diagnostyce i leczeniu nowotworów |
ES04728755.2T ES2535813T3 (es) | 2003-04-23 | 2004-04-22 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido N-glicolil-GM3 y su uso en el diagnóstico y tratamiento de tumores |
TW093111267A TWI343923B (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumors |
EA200501653A EA008353B1 (ru) | 2003-04-23 | 2004-04-22 | Рекомбинантные антитела и фрагменты, узнающие n-гликолил gm3 ганглиозид и их применение в диагностике и лечении злокачественных опухолей |
JP2006504218A JP2006524194A (ja) | 2003-04-23 | 2004-04-22 | ガングリオシドn−グリコリルgm3を認識する組み換え抗体及び断片と、腫瘍の診断及び治療におけるその使用 |
MYPI20041468A MY144620A (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments which recognize n glycolil gm3 ganclioside and its use in diagnosis and treatment of tumors |
CN201210517262.6A CN103012586B (zh) | 2003-04-23 | 2004-04-22 | 识别n-乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用 |
KR1020057020182A KR20060006937A (ko) | 2003-04-23 | 2004-04-22 | 엔 글리콜릴 지엠3 강글리오사이드를 인식하는 재조합 항체및 단편 그리고 종양의 진단 및 치료에서 사용 |
YU20050795A RS51853B (en) | 2003-04-23 | 2004-04-22 | RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING N-GLYCOLYL GM3 GANGLIOZIDE AND THEIR USE IN TUMOR DIAGNOSIS AND TREATMENT |
HUE04728755A HUE025266T2 (en) | 2003-04-23 | 2004-04-22 | Recombinant Antibodies and Fragments Recognizing Ganglioside-N-Glycolyl GM3 and Their Use in Diagnosis and Treatment of Tumors |
EP04728755.2A EP1623997B1 (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours |
GEAP20049062A GEP20084476B (en) | 2003-04-23 | 2004-04-22 | Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours |
MXPA05011368A MXPA05011368A (es) | 2003-04-23 | 2004-04-22 | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores. |
RS20110319A RS20110319A3 (en) | 2003-04-23 | 2004-04-22 | RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING N-GLYCOLYL GM3 GANGLIOZIDE AND THEIR USE IN TUMOR DIAGNOSIS AND TREATMENT |
ARP040101389A AR044076A1 (es) | 2003-04-23 | 2004-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n- glicolil gm3 y su uso para diagnostico y tratamiento de tumores |
UY28289A UY28289A1 (es) | 2003-04-23 | 2004-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n-glicolil gm3 y su uso para diasnostico y tratamiento de tumores |
HR20050922A HRP20050922A2 (en) | 2003-04-23 | 2005-10-21 | Recombinant antibodies and fragments which recognize n-glycolil-gm3 ganglioside and its use in the diagnosis and treatment of tumours |
TNP2005000274A TNSN05274A1 (en) | 2003-04-23 | 2005-10-21 | Recombinant antibodies and fragments which recognize n-glycolyl-gm3 ganglioside and its use in the diagnosis and treatment of tumours |
IL171541A IL171541A (en) | 2003-04-23 | 2005-10-23 | Recombinant antibodies and segments that detect n - glycolyl - gm3 ganglioside and their use in tumor diagnosis and treatment |
LT2005101A LT5353B (lt) | 2003-04-23 | 2005-11-21 | Rekombinantiniai antikūniai ir jų fragmentai, atpažįstantys n-glikolil-gm3 gangliozidus, ir jų panaudojimas auglių diagnozei ir gydymui |
LVP-05-152A LV13427B (en) | 2003-04-23 | 2005-11-22 | Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours |
ZA200509457A ZA200509457B (en) | 2003-04-23 | 2005-11-22 | Recombinant antibodies and framents recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumors. |
CR8105A CR8105A (es) | 2003-04-23 | 2005-11-25 | Anticuerpos recombinantes y fragmentos que reconocen el ganglosido n-glicolil gm3 y su uso para diagnostico y tratamiento de tumores |
HK13110760.2A HK1183492A1 (en) | 2003-04-23 | 2013-09-19 | Recombinant antibodies ana fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours n- gm3 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
Publications (1)
Publication Number | Publication Date |
---|---|
CU23403A1 true CU23403A1 (es) | 2009-08-04 |
Family
ID=40261249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1623997B1 (es) |
JP (1) | JP2006524194A (es) |
KR (1) | KR20060006937A (es) |
CN (2) | CN1809592A (es) |
AR (1) | AR044076A1 (es) |
AU (1) | AU2004232391B2 (es) |
BR (1) | BRPI0409664A (es) |
CA (1) | CA2523449C (es) |
CL (1) | CL2004000843A1 (es) |
CR (1) | CR8105A (es) |
CU (1) | CU23403A1 (es) |
EA (1) | EA008353B1 (es) |
ES (1) | ES2535813T3 (es) |
GE (1) | GEP20084476B (es) |
HK (1) | HK1183492A1 (es) |
HR (1) | HRP20050922A2 (es) |
HU (1) | HUE025266T2 (es) |
IL (1) | IL171541A (es) |
LT (1) | LT5353B (es) |
LV (1) | LV13427B (es) |
MX (1) | MXPA05011368A (es) |
MY (1) | MY144620A (es) |
NZ (1) | NZ543345A (es) |
PE (1) | PE20050422A1 (es) |
PL (1) | PL1623997T3 (es) |
RS (2) | RS20110319A3 (es) |
SI (1) | SI1623997T1 (es) |
TN (1) | TNSN05274A1 (es) |
TW (1) | TWI343923B (es) |
UY (1) | UY28289A1 (es) |
WO (1) | WO2004094477A1 (es) |
ZA (1) | ZA200509457B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2261335T (pt) | 1998-11-27 | 2017-09-08 | Ucb Pharma Sa | Composições e métodos para aumentar a mineralização óssea |
MEP2808A (xx) | 2003-06-16 | 2010-02-10 | Celltech R & D Inc | Antitijela specifična za sklerositin i metode za povećanje mineralizacije kostiju |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
EP3195880B1 (en) | 2010-05-14 | 2019-11-27 | Amgen Inc. | High concentration anti-sclerostin antibody formulations |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
JP2014511842A (ja) | 2011-03-25 | 2014-05-19 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体結晶およびその製剤 |
SI2739311T1 (en) | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
AU2012362898B2 (en) | 2011-12-28 | 2017-11-09 | Amgen, Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
CU24120B1 (es) | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
CN104619342A (zh) | 2012-07-05 | 2015-05-13 | Ucb医药有限公司 | 骨疾病的治疗 |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
EP3397756B1 (en) | 2015-12-30 | 2023-03-08 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
MX2020004229A (es) | 2017-10-25 | 2020-07-22 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
US11466079B2 (en) | 2018-03-30 | 2022-10-11 | Amgen Inc. | C-terminal antibody variants |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
KR102344948B1 (ko) * | 2018-09-03 | 2021-12-28 | 세종대학교산학협력단 | 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4 |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN110208409A (zh) * | 2019-06-05 | 2019-09-06 | 中国海洋大学 | 一种乳腺癌的生物标志物及其应用 |
WO2021123908A1 (en) | 2019-12-20 | 2021-06-24 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2270425T3 (es) * | 1994-01-25 | 2007-04-01 | Elan Pharmaceuticals, Inc. | Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4. |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
CA2203236A1 (en) | 1994-10-28 | 1996-05-09 | Ira Pastan | Tumor-specific antibody fragments, fusion proteins, and uses thereof |
WO1997002290A1 (fr) * | 1995-06-30 | 1997-01-23 | Mochida Pharmaceutical Co., Ltd. | ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR |
US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
-
2003
- 2003-04-23 CU CU20030092A patent/CU23403A1/es unknown
-
2004
- 2004-04-21 PE PE2004000397A patent/PE20050422A1/es not_active Application Discontinuation
- 2004-04-21 CL CL200400843A patent/CL2004000843A1/es unknown
- 2004-04-22 MY MYPI20041468A patent/MY144620A/en unknown
- 2004-04-22 GE GEAP20049062A patent/GEP20084476B/en unknown
- 2004-04-22 SI SI200432242T patent/SI1623997T1/sl unknown
- 2004-04-22 NZ NZ543345A patent/NZ543345A/en not_active IP Right Cessation
- 2004-04-22 JP JP2006504218A patent/JP2006524194A/ja active Pending
- 2004-04-22 PL PL04728755T patent/PL1623997T3/pl unknown
- 2004-04-22 CN CNA2004800174578A patent/CN1809592A/zh active Pending
- 2004-04-22 MX MXPA05011368A patent/MXPA05011368A/es active IP Right Grant
- 2004-04-22 TW TW093111267A patent/TWI343923B/zh not_active IP Right Cessation
- 2004-04-22 AU AU2004232391A patent/AU2004232391B2/en not_active Ceased
- 2004-04-22 WO PCT/CU2004/000006 patent/WO2004094477A1/es active IP Right Grant
- 2004-04-22 RS RS20110319A patent/RS20110319A3/en unknown
- 2004-04-22 ES ES04728755.2T patent/ES2535813T3/es not_active Expired - Lifetime
- 2004-04-22 CN CN201210517262.6A patent/CN103012586B/zh not_active Expired - Fee Related
- 2004-04-22 EA EA200501653A patent/EA008353B1/ru not_active IP Right Cessation
- 2004-04-22 BR BRPI0409664-9A patent/BRPI0409664A/pt not_active Application Discontinuation
- 2004-04-22 EP EP04728755.2A patent/EP1623997B1/en not_active Expired - Lifetime
- 2004-04-22 KR KR1020057020182A patent/KR20060006937A/ko not_active Application Discontinuation
- 2004-04-22 RS YU20050795A patent/RS51853B/en unknown
- 2004-04-22 HU HUE04728755A patent/HUE025266T2/en unknown
- 2004-04-22 CA CA2523449A patent/CA2523449C/en not_active Expired - Lifetime
- 2004-04-23 UY UY28289A patent/UY28289A1/es not_active Application Discontinuation
- 2004-04-23 AR ARP040101389A patent/AR044076A1/es active IP Right Grant
-
2005
- 2005-10-21 TN TNP2005000274A patent/TNSN05274A1/en unknown
- 2005-10-21 HR HR20050922A patent/HRP20050922A2/xx not_active Application Discontinuation
- 2005-10-23 IL IL171541A patent/IL171541A/en active IP Right Grant
- 2005-11-21 LT LT2005101A patent/LT5353B/lt not_active IP Right Cessation
- 2005-11-22 ZA ZA200509457A patent/ZA200509457B/en unknown
- 2005-11-22 LV LVP-05-152A patent/LV13427B/en unknown
- 2005-11-25 CR CR8105A patent/CR8105A/es not_active Application Discontinuation
-
2013
- 2013-09-19 HK HK13110760.2A patent/HK1183492A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU23403A1 (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores | |
PH12018501554A1 (en) | Ror1 antibody compositions and related methods | |
CO2020000357A2 (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
BR112021018694A2 (pt) | Vesículas extracelulares para distribuição de vacina | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
BR112019010356A2 (pt) | molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo | |
MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
MD3313884T2 (ro) | Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora | |
CR11374A (es) | Proteinas humanas de union a antigenos del gm-csf | |
AR066987A1 (es) | Anticuerpo monoclonal contra proteina beta-amiloide | |
AR071304A1 (es) | Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer | |
AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
ECSP066379A (es) | Anticuerpos rg1 y usos de los mismos | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
MX2009009926A (es) | Anticuerpo tumor-especifico humano monoclonal. | |
PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
MX2023002330A (es) | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. | |
BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
NZ750948A (en) | Anti-gp73 antibodies and immunoconjugates | |
MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
ECSP056112A (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores | |
MX2020011385A (es) | Anticuerpos terapeuticos que se unen antigenos de lewis b y lewis y biantenarios. |